Collaborations with antibodies for type 2 diabetes

Our type 2 diabetes candidates are a part of a collaboration with a top 10 pharma: together we co-develop antibodies identified with our Abiprot™ platform.

About type 2 diabetes

The condition is a chronic endocrine disorder characterized by high blood sugar (hyper-glycemia) due to diminished effects of insulin, the hormone responsible for regulating sugar levels in the blood. Type 2 diabetes is considered insulin-independent, as the issue is cell desensitization to the hormone, which means increased levels of the hormone do not improve the condition. Around 380 million people globally are estimated to have type 2 diabetes, which is the majority of people affected by diabetes. According to an estimation from WHO, more than 1.5 million people die annually as a direct consequence of diabetes.1

Market potential

The American Diabetes Association recently published a report in which the total cost of patients diagnosed with diabetes in 2017 was estimated at USD 327 billion. This included USD 237 billion in direct medical costs and USD 90 billion in reduced productivity.2 While risk factors for type 2 diabetes include genetic predisposition and obesity, nearly 90% of patients are treated with pharmacological means rather than lifestyle adjustments alone.3  4

Therefore, the large therapeutic market for type 2 diabetes is thought to amount to over USD 26 billion annually in the EU5 (France, Germany, Italy, Spain and UK), Japan and the US combined.

1. World Health Organization. Global report on diabetes. World Health Organization, 2016.

2. American Diabetes Association. “Economic Costs of Diabetes in the US in 2017.” Diabetes care 41.5 (2018): 917.

3. Datamonitor Healthcare’s proprietary diabetes survey, May 2016.

4. Datamonitor Healthcare’s Forecast: Type 2 Diabetes 2016–25